Navigation Links
Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
Date:9/17/2007

First internal candidate to enter Phase 2 clinical development

PRINCETON, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the initiation of a Phase 2a clinical study of PS433540, the company's lead internal product candidate. PS433540 is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically proven mechanisms of action in a single compound. The compound works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Preclinical studies have shown that PS433540 is highly selective for the AII receptor sub-type 1 and the ET receptor sub-type A. As such PS433540 combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule. There are considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

The objective of the Phase 2a randomized, double-blind, placebo- controlled, parallel-group study is to evaluate the compound's safety and efficacy in subjects with Stage I and Stage II hypertension. This multi- center trial is expected to enroll 170 subjects. After a lead-in period, patients will be randomized into three study arms (placebo and two active arms
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 EarlySense, the market ... the prize for ,Best Novel Idea, at the 8 ... Teams International Conference, hosted this year in the UK ... a clinical research team studying the impact of the ... Los Angeles . The prize was ...
(Date:5/23/2013)...  MedVantx, Inc., the company that has pioneered a ... the Company has completed a major expansion of its ... and the upgrade of its systems to offer a ... specialty home delivery pharmacy in Sioux Falls, ... physicians, health systems and payors novel distribution services, as ...
(Date:5/23/2013)... NEW YORK , May 23, 2013  Echo ... has committed to waive down the Acceptance Threshold from ... Affected plus one Elan Share in accordance with the ... to the conditions summarized below. Under the ... to acquire Elan (NYSE: ELN ) for ...
Breaking Medicine Technology:Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10
... , NEW YORK, ... research report is available in its catalogue: , ... 2009 (15 Countries) , http://www.reportlinker.com/p0166835/European-Markets-for-Drug-Eluting-and-Bare-Metal-Stents-2009-15-Countries.html ... encompasses Germany, France, the United Kingdom (U.K.), Italy, Spain, ...
... , NEW YORK, Dec. ... report is available in its catalogue: , Radiopharmaceuticals ... http://www.reportlinker.com/p0164273/Radiopharmaceuticals---A-US-and-European-Market-Analysis.html , The market for radiopharmaceuticals continues ... acceptance and utilization of nuclear medicine equipment, as well ...
Cached Medicine Technology:Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10
(Date:5/23/2013)... In his pulse-quickening novel, “The AIDS Covenant” (published ... trust your government?” , In the “The AIDS Covenant,” readers ... London ’s Heathrow Airport. His American colleague, Alan Milner ... him to arrive at his Sierra Nevada ski-lodge. ... doubts about the government’s report. When Alan learns that Owen ...
(Date:5/23/2013)... CT (PRWEB) May 23, 2013 ... satisfaction and perception management tools, and ASCA, the ... develop the new ASCA Benchmarking Program. Voyance ... surveying technology and national benchmarking experience to support ... a comprehensive, state-of-the-art benchmarking tool. , “Voyance is ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Funeral Financials ... Memorial Day to the EOD Memorial Foundation ... be the greatest victims from the war. , ... originated in 1941 before the U.S. was even at ... Forces are identified with the Explosive Ordnance Disposal Badge. ...
(Date:5/23/2013)... By Denise Mann HealthDay Reporter , , THURSDAY, ... of Americans take to help treat hip and knee ... increase risk for developing glaucoma, a small new study ... there is an increase of intraocular pressure (IOP) or ... of the leading causes of blindness. ...
(Date:5/23/2013)... when a woman harried by hot flashes says she,s ... published online in Menopause , the journal of ... objective tests that what these women say about their ... showed that hot flashes were related to memory problems, ... there was a relationship between hot flashes and what ...
Breaking Medicine News(10 mins):Health News:New Book “The AIDS Covenant” by Roy Harris Delivers Intriguing, Captivating Story 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3
... Reporter , TUESDAY, Jan. 18 (HealthDay News) -- Preliminary ... treatment for multiple sclerosis can help relieve fatigue and ... of the claims. The debate started in 2009, ... published an intriguing study that suggested that a blockage ...
... News) -- In a study finding that may not ... strong negative impact on how long it takes someone to ... Researchers recruited more than 5,000 Australian twins in the early ... which some became alcohol-dependent. The study also looked at the ...
... at Rochester Institute of Technology indicates that the incidence ... is more than 25 percent higher among deaf and ... shows a direct correlation between childhood maltreatment and higher ... adulthood. The study, which was presented at the ...
... (HealthDay News) -- Kidneys from live donors that are transported ... use in transplants as a kidney from a donor in ... Researchers followed up on 56 kidneys from live donors ... States and Canada. All of the transplanted organs survived and ...
... Maintaining periodontal health may contribute to a healthy ... Journal of Periodontology . A new study suggests that ... such as chronic obstructive pulmonary disease (COPD) and pneumonia. ... upper throat are inhaled into the lower respiratory tract, ...
... has been issued a US patent claiming a method ... their surfaces. The method, discovered by John Cambier, PhD, ... Jewish Health, holds promise for treatment of B-cell mediated ... and rejection of organ transplants. This therapeutic approach has ...
Cached Medicine News:Health News:Vein-Opening Treatment for MS Stirs Controversy 2Health News:Vein-Opening Treatment for MS Stirs Controversy 3Health News:Vein-Opening Treatment for MS Stirs Controversy 4Health News:Study: Abuse rates higher among deaf and hard-of-hearing children compared with hearing youths 2Health News:Donor Kidneys Travel Safely, Study Finds 2Health News:Healthy gums may lead to healthy lungs 2Health News:Patent awarded for method to dampen immune response 2
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... Pro is a portable, easy-to-use device ... parameters PT, APTT, and ACT. It ... hospitals and medical offices for hematology ... catheterization laboratories, and dialysis centers for ...
Tenderlett finger incision devices are designed to fit the contour of the finger. Tenderlett is available in three different incision depths from toddler to adult and color-code for easy identificat...
The Unistik 3 family of single use safety lancets has 4 models for use across all clinical environments....
Medicine Products: